Boehringer Ingelheim microParts, with its new production facility, is doubling its annual production capacity to 20 million inhalation devices (Respimat Soft Mist Inhaler).
The expansion also involves the creation of new, modern workstations, as Respimat production will require up to 150 additional employees at full capacity.
The Respimat Soft Mist Inhaler from Boehringer Ingelheim is an atomiser that delivers medication for the treatment of respiratory diseases.
Boehringer Ingelheim said that two-thirds of the investment volume was spent on the technical equipment of the building and the production systems.
